NANOVIRICIDES, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | $5.5M | $5.4M | $6.4M |
| SG&A Expense | $4.0M | $3.1M | $2.6M |
| Operating Income | $-9.6M | $-8.5M | $-8.9M |
| Operating Margin | — | — | — |
| Interest Expense | — | $49.8K | $938 |
| Pretax Income | — | — | — |
| Income Tax Expense | — | — | — |
| Net Income | $-9.5M | $-8.3M | $-8.6M |
| Net Margin | — | — | — |
| EPS (Basic) | $-0.63 | $-0.70 | $-0.74 |
| EPS (Diluted) | $-0.63 | $-0.70 | $-0.74 |
| Shares Outstanding (Basic) | 15.1M | 11.9M | 11.6M |
| Shares Outstanding (Diluted) | 15.1M | 11.9M | 11.6M |
| Dividends Per Share | — | — | — |